HealthInvest Partners’s Neurocrine Biosciences NBIX Stock Holding History

HealthInvest Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Sell	72,898 -16,787	-19%	-$2.49M	3.31%	9
2026 Q1	$7.85M	Sell	89,685 -5,111	-5%	-$678K	2.54%	20
2025 Q4	$13.4M	Sell	94,796 -7,829	-8%	-$1.13M	4.29%	5
2025 Q3	$1.53M	Buy	102,625 +14,233	+16%	+$1.93M	5.67%	3
2025 Q2	$11.1M	Buy	88,392 +12,511	+16%	+$1.43M	4.75%	4
2025 Q1	$8.39M	Buy	75,881 +8,118	+12%	+$1.03M	3.71%	11
2024 Q4	$9.29M	Buy	67,763 +7,156	+12%	+$885K	4.41%	8
2024 Q3	$6.98M	Buy	60,607 +36,977	+156%	+$5.07M	3.28%	12
2024 Q2	$3.25M	Sell	23,630 -19,850	-46%	-$2.72M	1.98%	14
2024 Q1	$6M	Buy	43,480 +30,863	+245%	+$4.21M	3.65%	5
2023 Q4	$1.66M	Buy	+12,617	New	+$1.45M	1.3%	22
2022 Q4	$22.2K	Buy	+186	New	+$21.8K	0.04%	29

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HealthInvest Partners's NBIX Position: Q2 2026 in Review

HealthInvest Partners reduced its Neurocrine Biosciences (NBIX) stake by 19% in Q2 2026, selling an estimated $2.49M and leaving 72,898 shares worth $12.3M. The position accounts for 3.31% of the portfolio, ranked #9.

HealthInvest Partners first reported a position in NBIX in Q4 2022 and has held it in 12 quarters since. The position peaked at $13.4M in Q4 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

HealthInvest Partners held 72,898 shares of Neurocrine Biosciences worth $12.3M as of Q2 2026.
HealthInvest Partners sold 16,787 Neurocrine Biosciences shares in Q2 2026, an estimated $2.49M.
Neurocrine Biosciences made up 3.31% of HealthInvest Partners's portfolio in Q2 2026, its #9 holding.
HealthInvest Partners first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 12 quarters since.
HealthInvest Partners's Neurocrine Biosciences position peaked at $13.4M in Q4 2025.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.